BIOMUNEX has established an in-house discovery process to identify innovative pairs of targets to create innovative BiXAb® antibodies.

BIOMUNEX also assembles cutting-edge national and international academic teams and experts to discover new targets and new target pairs and advance the development of immuno-therapeutics for the treatment of solid tumor cancers. BIOMUNEX is currently collaborating with several renowned and major academic institutions such as:

  • Dr. Sebastian Amigorena and his team at Institut Curie in Paris, one of the most renowned research academic institutions in Europe. Recurrent Collaboration with the Institut Curie is focused on the development of the disruptive MAIT cell redirection approach and the BiXAb-MAIT engagers.
  • The Montpellier Cancer Research Institute (IRCM, Institut de Recherche en Cancérologie de Montpellier; Inserm 1194, Institut régional du Cancer de Montpellier, Montpellier, France), led by Dr. Thierry Chardès, as part of a program funded by the French National Research Agency, that has enabled the identification of a new bi-specific antibody that is more effective than standard therapeutic options in the treatment of pancreatic cancer.
  • The Universitätsklinikum Schleswig-Holstein (UKSH), one of the largest medical centers in Europe located in Kiel, Germany, where BIOMUNEX is collaborating with the teams of Professor Matthias Peipp, Director of the Department of Antibody-Based Immunotherapy, and Professor Daniela Wesch, Institute of immunology, for the evaluation of some of its lead drug candidates in immuno-oncology, including several of its MAIT engagers.